Inclusion Criteria:

   - Histologically confirmed carcinoma of the kidney (clear-cell predominance)

   - Have had at least 2 prior systemic treatments for renal cell carcinoma (RCC)

   - Have at least 1 extracranial metastasis that is amenable to radiation and at least 1
   other site of disease that is measurable by Response Evaluation Criteria in Solid
   Tumors (RECIST)

   - Subjects must provide written informed consent prior to performance of study-specific
   procedures or assessments, and must be willing to comply with treatment and follow up

   - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

   - Absolute neutrophil count (ANC) >= 0.75 x 10^9/L

   - Absolute lymphocyte count (ALC) >= 0.5 X 10^9/L

   - Hemoglobin >= 8 g/dL

   - Platelets >= 50 X 10^9/L

   - Total bilirubin =< 3 X upper limit of normal (ULN)

   - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN

   - Serum creatinine =< 2.1 X ULN (or creatinine clearance of > 50 cc/min)

Exclusion Criteria:

   - History of other malignancies within 5 years prior to enrollment except for tumors
   with a negligible risk for metastasis or death, such as adequately controlled basal
   cell carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix,
   early-stage bladder cancer, or low-grade endometrial cancer

      - Malignancies that have undergone a putative surgical cure (i.e., localized
      prostate cancer post-prostatectomy) within 5 years prior to enrollment may be
      discussed with the lead primary investigator

   - History or clinical evidence of central nervous system (CNS) metastases or
   leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
   metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure
   medication for more than 1 week within 6 months prior enrollment

   - Presence of uncontrolled infection

   - Evidence of active bleeding or bleeding diathesis; any medical condition requiring
   systemic anticoagulation (including anti-platelet agents)

   - Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
   could interfere with subject's safety, provision of informed consent, or compliance to
   procedures

   - Pregnant and breastfeeding women are excluded; as well as women of child-bearing
   potential who are unwilling or unable to use an acceptable method of birth control
   (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the
   duration of the study